ABSTRACT
OBJECTIVE:To evaluate efficacy and safety of caspofungin for non-effect/intolerant to fluconazole in patients with invasive fungal infetion(IFI) in intensive care unit(ICU).METHODS:A retrospective analysis was conducted in 14 IFI patients in ICU who was without effect/intolerant to gluconazole.They were treated with caspofungin in a dose of 70 mg in the first day,and then in a dose 50 mg?d-1 for 3～28 d.RESUITS:Of total 14 cases,2 cases had been diagnosed including 1 case of candidemia albicans and 1 case of pulmonary candidosis glabrata;5 probable cases including 2 cases of pulmonary aspergillus species,2 cases of pulmonary candidosis albicans and 1 cases of pulmonary candidosis parapsilosis;In 7 suspected cases pathogen fungus were not found out.One patient died of respiratory failure at third day of treatment.Clinical efficacy of death case cannot be evaluated.Of total evaluable 13 cases,2 were cured(2/13,15.4%),4 markedly effective cases(4/13,30.8%),2 improved cases(2/13,15.4%) and 5 ineffective cases(5/13,38.5%),the overall effective rate was 46.2%.Caspofungin can be tolerated by all patients during therapy without drug related adverse reaction.CONCLUSION:Caspofungin is certain of efficacy and safety for non-effect/intolerant to fluconazole in IFI patients in ICU,and is the first choice for IFI patients in ICU.
ABSTRACT
OBJECTIVE:TO evaluate the economic effectiveness of the8medication schemes for preventing postoperation infections of cholecystitis and cholelithiasis.METHODS:The principle of pharmacoeconomics was adopted in the cost-effec-tiveness analysis of8medication schemes,ampicillin+amikacin+metroidazole(A),ampicloxacillin+metroidazole(B),lev-ofloxacin+metroidazole(C),cefoperazone/sulbactam+metroidazole(D),ceftazidime+metroidazole(E),piperacillin/tazobac-tam+metroidazole(F),ceftriaxone+metroidazole(G),cefotaxim/sulbactam+metroidazole(H).RESULTS:The costs for A,B,C,D,E,F,G and H schemes were72.75,497.75,339.75,392.75,1213.95,931.75,315.75and1409.75yuan respec-tively,with scheme A the lowest in cost;No significant differences were found in effectiveness among the8schemes.CON-CLUSION:Scheme A is superior to the others.